[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:liver-failure":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":162,"states":163},"Liver Failure",25,22,[8,16,22,28,34,40,46,52,58,64,70,75,81,87,93,99,105,111,118,124,130,136,142,150,155],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07559474","A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment",[12],"Phase 1","RECRUITING","2026-08-26T02:16:42.787115Z","2026-06-17T02:29:30.057787Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04617522","Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment",[12],"2026-08-26T02:15:46.655893Z","2026-05-05T02:43:29.682698Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06442436","A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)",[12],"2026-08-03T03:38:39.261584Z","2026-05-05T02:43:28.514122Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT06962332","Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)",[12],"2026-08-26T02:16:38.053590Z","2026-05-05T02:43:28.510767Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT07023354","A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems",[12],"2026-08-26T02:16:15.345907Z","2026-05-05T02:43:28.471318Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":44,"content_modified":45},"NCT05484206","Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434",[12],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:27.914197Z",{"nct_id":47,"title":48,"phases":49,"status":13,"updated_at":50,"content_modified":51},"NCT07144111","A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib",[12],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:27.755509Z",{"nct_id":53,"title":54,"phases":55,"status":13,"updated_at":56,"content_modified":57},"NCT07342868","Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function",[12],"2026-08-03T02:54:41.410572Z","2026-05-05T02:43:27.063308Z",{"nct_id":59,"title":60,"phases":61,"status":13,"updated_at":62,"content_modified":63},"NCT06740799","Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment",[12],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:26.710510Z",{"nct_id":65,"title":66,"phases":67,"status":13,"updated_at":68,"content_modified":69},"NCT07486102","A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems",[12],"2026-08-26T02:17:58.890423Z","2026-04-29T02:57:57.069298Z",{"nct_id":71,"title":72,"phases":73,"status":13,"updated_at":68,"content_modified":74},"NCT06871111","The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial",[12],"2026-05-05T02:43:28.508280Z",{"nct_id":76,"title":77,"phases":78,"status":13,"updated_at":79,"content_modified":80},"NCT07358546","A Study of Efimosfermin Alfa in Adults With Hepatic Impairment",[12],"2026-08-26T02:16:54.876240Z","2026-07-05T05:32:16.678763Z",{"nct_id":82,"title":83,"phases":84,"status":13,"updated_at":85,"content_modified":86},"NCT07248839","A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment",[12],"2026-08-26T02:16:18.872924Z","2026-06-14T18:39:22.239137Z",{"nct_id":88,"title":89,"phases":90,"status":13,"updated_at":91,"content_modified":92},"NCT07677358","A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease",[12],"2026-08-26T02:18:34.622081Z","2026-07-05T03:45:20.438143Z",{"nct_id":94,"title":95,"phases":96,"status":13,"updated_at":97,"content_modified":98},"NCT07231991","A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function",[12],"2026-08-26T02:19:28.327680Z","2026-05-05T02:43:29.585013Z",{"nct_id":100,"title":101,"phases":102,"status":13,"updated_at":103,"content_modified":104},"NCT07457229","Phase 1 Open-Label Study of Radiprodil Pharmacokinetics, Safety, and Tolerability in Hepatically Impaired Participants",[12],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:29.074172Z",{"nct_id":106,"title":107,"phases":108,"status":13,"updated_at":109,"content_modified":110},"NCT06997276","Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib",[12],"2026-08-26T02:17:05.172421Z","2026-05-05T02:43:27.508394Z",{"nct_id":112,"title":113,"phases":114,"status":13,"updated_at":116,"content_modified":117},"NCT05726032","Empagliflozin in Patients With Cirrhosis and Ascites",[115],"Phase 2","2026-08-26T02:15:58.452248Z","2026-05-05T02:43:27.253356Z",{"nct_id":119,"title":120,"phases":121,"status":13,"updated_at":122,"content_modified":123},"NCT07219550","A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)",[12],"2026-08-03T02:46:25.472834Z","2026-05-05T02:35:31.871537Z",{"nct_id":125,"title":126,"phases":127,"status":13,"updated_at":128,"content_modified":129},"NCT07519135","A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function",[12],"2026-08-26T02:17:16.980188Z","2026-05-05T02:35:31.863124Z",{"nct_id":131,"title":132,"phases":133,"status":13,"updated_at":134,"content_modified":135},"NCT07546760","A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234",[12],"2026-08-26T02:18:41.390601Z","2026-04-29T02:57:57.177577Z",{"nct_id":137,"title":138,"phases":139,"status":13,"updated_at":140,"content_modified":141},"NCT07269301","A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function",[12],"2026-08-26T02:16:51.982021Z","2026-04-29T02:57:57.147503Z",{"nct_id":143,"title":144,"phases":145,"status":147,"updated_at":148,"content_modified":149},"NCT07634562","TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation",[146],"Phase 1\u002FPhase 2","NOT_YET_RECRUITING","2026-08-26T02:16:20.336282Z","2026-06-14T18:39:22.251799Z",{"nct_id":151,"title":152,"phases":153,"status":147,"updated_at":91,"content_modified":154},"NCT03606538","MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function",[12],"2026-05-05T02:43:27.064614Z",{"nct_id":156,"title":157,"phases":158,"status":159,"updated_at":160,"content_modified":161},"NCT07578441","VitaSmart HOPE System: Bridge to HOPE Registry",[],"ENROLLING_BY_INVITATION","2026-08-26T02:15:59.318403Z","2026-06-16T05:54:07.895572Z",[],[164,168,172,176],{"state":165,"count":166,"slug":167},"Florida",17,"florida",{"state":169,"count":170,"slug":171},"Texas",14,"texas",{"state":173,"count":174,"slug":175},"California",8,"california",{"state":177,"count":178,"slug":179},"Arizona",4,"arizona"]